New combo tackles Drug-Resistant liver cancer in small trial
NCT ID NCT05718882
First seen Apr 26, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This study tested a combination of two drugs (lenvatinib and VIC-1911) in 5 adults with advanced liver cancer that no longer responded to lenvatinib alone. The goal was to see if the combo was safe and could slow cancer growth. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.